Ftse Mib
34.339,32
0,55%
DAX
18.686,60
1,07%
S&P 500
5.214,08
0,51%
NASDAQ
16.346,26
0,27%
Bitcoin
62.911,55
-0,22%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Chemomab Therapeutics Ltd (CMMB) Chemomab Therapeutics Ltd (CMMB) Notizie

Chemomab Therapeutics Ltd

CMMB
0,81
0,085 (11,72%)
10 Mag 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Ricevuta di Deposito
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
09/5/202413:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
09/5/202413:00GLOBEChemomab Therapeutics Announces First Quarter 2024 Financial..
08/5/202413:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
08/5/202413:00GLOBEChemomab Therapeutics Granted 180-Day Extension by Nasdaq to..
02/5/202413:00GLOBEChemomab Therapeutics to Present at 2024 Aegis Virtual..
24/4/202413:00GLOBEChemomab Therapeutics to Report First Quarter 2024 Financial..
18/4/202413:00GLOBEChemomab Reports New Peer-Reviewed Publication Reinforcing..
02/4/202413:00GLOBEChemomab to Host Virtual Key Opinion Leader Webinar on..
25/3/202412:06GLOBEChemomab Awarded New European Patent for CM-101, Its..
07/3/202413:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
07/3/202413:00PRNUSChemomab Therapeutics Announces Year End and Fourth Quarter..
05/3/202413:00PRNUSChemomab Therapeutics to Participate in Leerink Global..
20/2/202415:20APSBiotech Shares Massively Bid Up Before Opening Bell
20/2/202413:00PRNUSChemomab Awarded New Patents for CM-101, Its First-in Class..
14/2/202413:00PRNUSChemomab Therapeutics to Report Fourth Quarter and Full Year..
05/2/202413:00PRNUSChemomab Therapeutics to Participate in Upcoming Investor..
30/1/202413:00PRNUSChemomab Therapeutics Announces New Publication Reinforcing..
03/1/202413:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
03/1/202413:00PRNUSChemomab Announces Completion of Patient Enrollment in..
16/11/202313:00PRNUSChemomab Presentation at ACR Convergence 2023 Provides..
15/11/202322:35EDGAR2Form SC 13D/A - General statement of acquisition of..
15/11/202313:00PRNUSChemomab Therapeutics Receives FDA Fast Track Designation..
13/11/202314:00PRNUSChemomab Presents New Clinical Data Supporting CM-101's..
09/11/202314:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
09/11/202314:00PRNUSChemomab Therapeutics Announces Third Quarter 2023 Financial..
06/11/202322:15PRNUSChemomab Therapeutics Discloses Receipt of Nasdaq Notice..
06/11/202306:15EDGAR2Form EFFECT - Notice of Effectiveness
30/10/202313:33EDGAR2Form F-3/A - Registration statement by foreign private..
30/10/202312:00PRNUSChemomab Therapeutics to Report Third Quarter 2023 Financial..
26/10/202313:00PRNUSChemomab Therapeutics to Present at Upcoming Scientific..
16/10/202322:25EDGAR2Form F-3 - Registration statement by foreign private issuers
28/9/202313:00PRNUSChemomab Therapeutics to Present Its CM-101 Clinical Program..
29/8/202313:00PRNUSChemomab Therapeutics to Present at the H.C. Wainwright 25th..
14/8/202314:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
14/8/202314:00PRNUSChemomab Therapeutics Announces Second Quarter 2023..
08/8/202312:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
05/7/202323:48EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/7/202321:49EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
28/6/202313:00PRNUSChemomab Therapeutics Announces Publication in JCI Insight..
26/6/202313:00PRNUSChemomab Therapeutics Presents Data Reinforcing the Clinical..
21/6/202313:00PRNUSChemomab Therapeutics Reports Positive Data from Secondary..
05/6/202313:00PRNUSChemomab Therapeutics Announces Executive Leadership Changes..
02/6/202315:00PRNUSPatient Data Presented at 2023 EULAR Congress Highlights How..
24/5/202313:00PRNUSChemomab Therapeutics to Participate in Upcoming Scientific..
11/5/202312:00PRNUSChemomab Therapeutics Announces First Quarter 2023 Financial..
Apertura: 0,735 Min: 0,6921 Max: 0,85
Chiusura: 0,725

La tua Cronologia

NASDAQ
CMMB
Chemomab Therapeutics
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network